Sign in to view Guangcheng’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Guangcheng’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
San Diego, California, United States
Sign in to view Guangcheng’s full profile
Guangcheng can introduce you to 10+ people at Z-Alpha Therapeutics
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
556 followers
500+ connections
Sign in to view Guangcheng’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Guangcheng
Guangcheng can introduce you to 10+ people at Z-Alpha Therapeutics
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Guangcheng
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Guangcheng’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
About
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Activity
556 followers
-
Guangcheng Jiang posted thisExcited to share that I’ll be presenting two posters at SNMMI 2025 in New Orleans (June 21-24)! 1️⃣ FL-261: A theranostic RDC vector for c-MET-positive cancers (#251656) 2️⃣ [⁶⁸Ga]Ga/[²²⁵Ac]Ac-FL-031: A theranostic pair targeting SSTR2-positive cancers (#251518) Looking forward to connecting and sharing our latest work in radiotheranostics! #SNMMI2025 #Theranostics #Radiopharmaceuticals #NuclearMedicine #cMET #SSTR2
-
Guangcheng Jiang reposted thisGuangcheng Jiang reposted thisFull-Life Technologies announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical trials of ²²⁵Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC). #FullLife #FDA #IND #Ac225 #mCRPC #radiopharmaceuticalsFull-Life Technologies Announces Clearance from FDA of IND Application for ²²⁵Ac-FL-020 for the Treatment of Metastatic Castration-Resistant ProstateFull-Life Technologies Announces Clearance from FDA of IND Application for ²²⁵Ac-FL-020 for the Treatment of Metastatic Castration-Resistant ProstateFull-Life Technologies
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisLooking back over 46 years, the chapters are clear. Youthful innocence. Coming of age. The college party. The vampire hours. The elevator down. Then the long, unglamorous work of putting Humpty Dumpty back together. — September 18th, 2002. I was 23, relapsing for a third time – this time with over a year of sobriety behind me. So I went into plain-sight hiding. Drinking by myself, during shifts, between shifts, and around the clock until I passed out. Two weeks in and seemingly no end in sight, my buddy Justin spotted me across that grungy Pier Ave bar. I cowered like a dog in shame, could barely make eye contact as he dragged me out of there, threw me in his car, and delivered me to my parents' doorstep for the final time. Next morning (~noon, still in bed), Mom hands me the phone with a new hardcore sponsor on the line. “Tim – meet me at my office in 1 hour”. Tough love and getting kicked to the curb was just around the corner for me, along with the realization that this was my last last chance. No money. No degree. No enablers left. Unemployable. Amends unmade. Totally depressed and non-functional. The gift of desperation had finally arrived. — I never went to grad school. But what I learned in my early 20s – through lived experience, not textbooks – didn't stay in "recovery world." It came with me when I eventually re-enrolled at UCSD to finish my undergrad. It came with me through 20+ years of finally adulting as an employee, spouse, son, father, & friend. It taught me how to live life on life's terms – and find some degree of happiness there, regardless of external circumstance. No cure. No magic pill. No arrival. Just the systematic doing of tiny things, consistently over time, often contrary to how I felt at the time. Plan to share more of these – stories connecting sobriety, leadership, relationships, lessons from nature, and the daily work of getting into action. Take what's useful. (pic from a few years ago standing under the SunGod @ UC San Diego 🧜♂️)
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisExcited to share that TippingPoint Biosciences (https://lnkd.in/gUJrDeek) just successfully closed an overscribed seed round and brought the total raise to 7 million dollars to date (https://lnkd.in/gVhNUiQu). Big shout-out to our prestigious investors-SOSV and LKS Fund (coleads), Sazze Partners, FreeFlow Ventures, StoryHouse Ventures, Sontag Innovation Fund, BrightEdge - American Cancer Society, XEIA Venture Partners and WeCAN, for having a LONG view and supporting NOVEL biology and platform. TippingPoint was co-founded by Laura Hsieh, PhD and renowned University of California, San Francisco biologist Geeta Narlikar PhD (member of the National Academy of Sciences and a AAAS). I have been advising Laura and Geeta and other members of the team for the past two years and witnessed how the team conducted great science very diligently and efficiently. I am looking forward to continuing helping the team accomplish more greatness in the next phase of growth.
-
Guangcheng Jiang liked thisIt's been an incredible journey to take a scientific concept from discovery to human trials and now this transition. I could not be more proud of the team that has made this moment a reality. Excited doesn't even begin to describe the feeling of having a partner with the knowledge, vision and resources to bring this to the many patients that will benefit from Exl-111. #Excellergy #Novartis #Allergy #CSUGuangcheng Jiang liked thisNovartis has agreed to acquire Excellergy, Inc., a private clinical-stage biotechnology company developing next-generation anti-IgE therapies for IgE-driven diseases. Excellergy’s lead asset, Exl-111, is a Phase 1, half-life extended and high-affinity anti-IgE antibody designed to dissociate receptor-bound IgE, with the potential to deliver faster and deeper suppression of IgE signaling than current anti-IgE approaches. In simple terms, it is designed to go beyond conventional anti-IgE therapy and could help improve symptom control for patients across a range of allergic diseases. The proposed acquisition also builds on deep Novartis expertise in IgE biology and strengthens the immunology pipeline, especially in the food allergy space. For more information: https://lnkd.in/gHaPPCu6
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisWatching my daughters grow up (too fast!) and looking around at the powerful women in my life, can’t help but think of how they model leadership qualities this world so desperately needs. Resilience. Patience. Restraint. Emotional intelligence & the ability to carry strength and softness in the same breath. Mom raised three boys (dad too, if we’re being honest), pulled me out of a dark spiral in my 20’s, and remains the person everyone turns to for advice born not out of logic but from empathy, wisdom, and all those “soft” qualities that are anything but. And my wife Monique - leading the charge as a high school PE teacher in a male‑dominated environment - carrying the perfect balance of tough & tender love as mom & “Coach Swift” to our oldest daughter Sophia. When we finally & fully hand over the reins to women, it’s hard not to imagine a healthier, more caring, more functional society. A couple of days ago Sophia texted me: “Dad, I won the scholarship” and included the essay she wrote. Solid writing aside, it was the awareness & ownership of growth from a 16 yr old that floored me (yes, girls are light years ahead of boys at that age 😉) “Lessons in Calculus, Chemistry, & Computer Science have taught me their intricacies and challenges; History textbooks have informed me of plights and mistakes of the past, and each year I am plunged further into the minutia of the English language and each rule that some word dares to contradict. Despite the academic value, it pales in comparison to what I learned through sports this past year.” She goes on to talk about going out for pole vaulting and struggling to clear the opening height (7ft) those first few comp’s. So she doubled down. Found an elite club 15 minutes away, trained twice a week on top of regular practice, pushing through 3hr conditioning sessions & the kind of “sometimes miserable” work that tests you physically & mentally. “Hard work, passion, & showing up became the lesson” according to Fifi. Watching kids take on new things, fall, get up, & try again is a reminder of how we adults slowly lose the courage to be beginners. We cling to comfort. We don’t want to suck or “fail” (🙋🏻♂️), so we stand on the sidelines… & unfortunately stop growing. An old sponsor used to remind me: “Willingness without action is fantasy.” Akin to not having have to *DO* anything to possess talent, you’re just born with it. Struggle, effort, perseverance… those are the qualities that define a person. Now in her sophomore year, Sophia’s vaulting 10ft and balancing AP classes, 4 to 6 practices a week, ASB / Dance Commitee leadership, & tutoring 8th grade girls in math before school. Her dream is to attend UCLA or Stanford on a sports scholarship and become a surgeon because of the care she received from doctors at age 5 for a rattlesnake bite. To the mothers, daughters, wives, & all the amazing women I’m fortunate to work alongside - THANK YOU for all you do. #InternationalWomensDay
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisThe FDA just made a move that could fundamentally change the treatment of plaque psoriasis. Yesterday, March 18, 2026, Icotrokinra (ICOTYDE™) was officially approved. Historically, if you wanted to target the IL-23 pathway with high precision, you needed an injectable biologic (like Tremfya or Skyrizi). Small molecule orals, while convenient, often struggle to match that specific "biologic-level" efficacy. Icotrokinra changes that by being a cyclic peptide. It’s small enough to be taken as a once-daily pill but precise enough to selectively block the IL-23 receptor with picomolar affinity. Beyond psoriasis, J&J is already pushing this molecule into Phase III for Ulcerative Colitis and Psoriatic Arthritis. We are witnessing a shift where the "biologic vs. oral" gap is finally closing. For those of us in the lab and the industry, this is a masterclass in peptide engineering—turning a complex protein-protein interaction into a stable, bioavailable oral dosage form.
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisThe most anticipated meeting in “America’s Finest City”. Look forward to connecting, reconnecting, catching up, running into…. Got invited to a special long-term member event- which reminds me that this is my 25th year being an #AACR member! When I first joined AACR in 2000, I was only a 2nd year graduate student- time’s flying and a lot of (good) things have happened since then. Also taking home court advantage, I am participating in the special programs for high school students, hoping to help inspire our next generation of scientists and physicians. Will be fun!
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisWeathered and bruised, but never beaten. Nothing entitled, everything earned. I am always captivated by the dramatic, rugged, and harsh scenery of the frontier lands. A strong sense of time, space, endurance, hope
-
Guangcheng Jiang liked thisGuangcheng Jiang liked thisJoin me at the LSX Investival Showcase USA, March 10-11, in Miami, where visionary life-science innovators secure game-changing capital and partnerships. Register here: https://lnkd.in/eYDVSaUZ #investival #biotechnology #biopharma #medicaldevices #digitalhealth
Experience & Education
-
Z-Alpha Therapeutics
******** ** *********
-
********
******* * ***
-
********* ************
********* ******* *********
-
*** ***** ***** **********
** ******** ******* undefined
-
-
****** **********
******** ** ******* * ** ******* *********
-
View Guangcheng’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View Guangcheng’s full profile
-
See who you know in common
-
Get introduced
-
Contact Guangcheng directly
Other similar profiles
Explore more posts
-
Agilent India
23K followers
Peptide therapeutics are scaling faster than ever. GLP-1 programs are moving from innovation to industrial reality and analytical rigor is now a differentiator, not a checkbox. As APAC emerges as a hub for peptide API development and CDMO manufacturing, labs need workflows that scale with confidence, from development through QC. Explore our latest resources built to power your GLP-1 development with reproducibility, speed, and regulatory alignment. Access Here: https://lnkd.in/dAdgC2su #Peptidetherapeutics #GLP1 #Biopharma #AgilentAPAC #AgilentIndia
15
-
Agilent Asia Pacific
14K followers
Peptide therapeutics are scaling faster than ever. GLP-1 programs are moving from innovation to industrial reality and analytical rigor is now a differentiator, not a checkbox. As APAC emerges as a hub for peptide API development and CDMO manufacturing, labs need workflows that scale with confidence, from development through QC. Explore our latest resources built to power your GLP-1 development with reproducibility, speed, and regulatory alignment. Access Here: https://lnkd.in/dAdgC2su #Peptidetherapeutics #GLP1 #Biopharma #AgilentAPAC #AgilentIndia
14
-
SellSyde.ai
197 followers
🚨 Cytek Biosciences, Inc. (CTKB) – Hold: Cytek shows signs of stabilization, but uncertainties remain. 📊 Earnings Snapshot (reported 2026-02-26): • EPS: -0.34 vs 0.02 est (-1819.5%) • Rev: 62.1M vs 58.8M est (+5.7%) This report is prompted by Cytek Biosciences' fourth-quarter earnings call for 2025, where the company reported an 8% year-over-year revenue increase despite operating in a challenging environment. The mixed fundamentals and cautious guidance lead to a decision to maintain a Hold rating. Upcoming Catalysts: - Continued growth in recurring revenue. - New product launches in 2026. - Stabilization of market conditions in EMEA and the U.S. 👇 **Read the full Stock Analysis:** #HealthCare #Earnings #Investing #SellSyde #StockMarket 2026-02-Fr 13:20:39
2
-
San Diego Biotech Networks
25K followers
SDBN Feed: Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors https://lnkd.in/g-Y89cYt TAIPEI and SAN DIEGO, Dec. 10, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global [...]
1
-
Society for Industrial and Applied Mathematics (SIAM)
19K followers
Inhibition constants are fundamental #parameters that quantify drug-drug interactions and guide #medication dosing. On the SIAM News blog, Hyeong Jun Jang, Yun Min Song, and Jae Kyoung Kim introduce their new method to estimate inhibition constants that increases accuracy and precision when compared to conventional estimation models. Learn more:https://lnkd.in/ec7JSEkW
1
-
freederia
187 followers
New Post: ## Scalable Chiral Discrimination Utilizing Machine Learning-Enhanced Circular Dichroism Spectroscopy for Glycan Analysis in Biopharmaceutical Development - https://lnkd.in/gw8bFnR3 Glycan analysis is a critical step in biopharmaceutical development, influencing drug efficacy, immunogenicity, and stability. Traditional methods like chromatography are time-consuming and often lack sufficient throughput for modern drug development pipelines. This research proposes a novel approach combining Circular Dichroism \(CD\) spectroscopy with advanced machine learning techniques to achieve rapid, scalable, and highly accurate \[…\]
-
BiotechTV
36K followers
𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T. Full video: https://lnkd.in/gqxWbM7s He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs. BiotechTV's coverage of the 2025 ASH Annual Meeting is brought to you by Klein Hersh. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen | Evaluate Ltd
156
-
San Francisco Biotech Networks
9K followers
SFBN Feed: BigHat inks Eli Lilly deal for AI antibody research, extends Series B https://lnkd.in/gtwgqemz BigHat Biosciences has added another pharma partner and more cash to its balance sheet as the antibody specialist prepares to enter the clinic next year. The Bay Area startup will announce a research deal with [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
-
Los Angeles Biotech Networks
1K followers
AMDI Submits 510(k) and CLIA Waiver Dual Submission to FDA https://lnkd.in/gvis7VyM SANTA ANA, Calif., Sept. 15, 2025 /PRNewswire/ — Today, Autonomous Medical Devices Incorporated (AMDI) announced its submission to the US Food and Drug Administration (FDA) of a dual 510(k) and CLIA Waiver application for the [...]
-
Global Bio & Investment Monthly
6K followers
T-E Meds and Asymchem Group Join Forces to Advance ADC Innovation T-E Meds (#諦醫生技), founded by "Father of Antibodies of Taiwan" Dr. Tze-Wen Chang (#張子文), has entered a strategic partnership with Hong Kong-listed CDMO leader Asymchem Group (#凱萊���). The collaboration aims to accelerate development in antibody-drug conjugates (ADCs) and other novel therapeutics, encompassing CDMO and CRO services across multiple pipelines. Asymchem will enhance T-E Med's ADC toolbox with its diverse payload-linker technologies, enabling safer and more effective therapies for global clients. Read more at 👇 https://reurl.cc/9DMx98 ➤ Follow us for more news and Taiwan biotech ecosystem updates: https://lnkd.in/gPb8fyrt #TEMeds #Asymchem #ADC #BiotechPartnership #CDMO #CRO #Antibody #ARC #Taiwan #China #HongKong
24
-
NB Health Laboratory Co., LTD.
150 followers
⭐️NBHL and FRONTEO Enter PoC Research Agreement to Accelerate Antibody Drug Discovery Leveraging AI and GPCR Antibody Platforms NBHL announced that it has entered into a Proof-of-Concept (PoC) research agreement with FRONTEO, Inc. to jointly advance the creation of an antibody drug pipeline. 👉 Read the full press release here: https://lnkd.in/g8RJm2WT This collaboration will harness FRONTEO’s Drug Discovery AI Factory (DDAIF), an AI-powered drug discovery support platform, alongside NBHL’s proprietary MoGRAA platform for GPCR-targeted antibody discovery: https://lnkd.in/gCfw3Bsx Under this agreement, the two companies will combine DDAIF’s capability to discover previously unreported disease-associated target molecules with MoGRAA’s strength in efficiently discovering highly selective antibodies against GPCRs, which have been difficult targets through conventional drug discovery approaches. The integration of these technologies aims to accelerate the development of innovative therapeutics targeting GPCRs. By advancing this initiative, NBHL and FRONTEO will leverage their complementary expertise and technologies to address unmet medical needs. The collaboration aspires to contribute to the realization of groundbreaking new therapies and to the improvement of patients’ quality of life (QOL). #AntibodyDrugDiscovery #GPCR #BiopharmaInnovation #AIDrugDiscovery #LifeScienceInvestment
7
-
PDA West Coast Chapter (PDA WCC)
3K followers
🎓 PDA WCC x University of San Francisco Roundtable Discussion – Career Conversations That Matter Last week, PDA West Coast Chapter (PDA WCC) partnered with the University of San Francisco to host an interactive Roundtable Discussion designed to help STEM students explore career pathways in the biotech and pharmaceutical industries. 💬 Through three rounds of small-group discussions, professionals shared personal stories and practical insights around topics such as: • Landing that first STEM role: from internships to full-time opportunities • Breaking into biotech: what different roles actually look like behind the job titles • Exploring interdisciplinary careers: how diverse majors like biology, engineering, chemistry, and computer science all contribute to biotech innovation Students engaged in thoughtful conversations, asked great questions, and gained real-world advice on navigating early careers. The event concluded with a networking hour, where students connected directly with industry professionals. 👏 A huge thank-you to our amazing volunteers and roundtable discussion leaders for sharing your time, experiences, and encouragement. Your stories continue to inspire the next generation of STEM professionals. Organizers: Stephanie Lee, Bob To, Shuhui Chen, Ph.D. Luwei Xie, MBA, MS, Cary Lai Round Table Discussion Volunteers: Abby Chiang, Jacinda Chen, Kaushik Thakkar, Shaun Camcam, Julie Kong, Melat Zewdie, Alaina Touchton, Autumn Lee, Negar Harati #PDAWCC #USF #BiotechCareers #STEMEducation #Networking #ProfessionalDevelopment
41
1 Comment -
ChemDiv, Inc.
3K followers
ChemDiv Continues R&D Services Support for Clywedog Therapeutics San Diego, CA — September 30, 2025 — ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease. https://lnkd.in/eBsjbFCw #ChemDiv
4
-
Chromatography & Mass Spectrometry
27K followers
Isomer discrimination, made clear. In peptide mapping of NISTmAb, EThcD produced ETD-diagnostic c+57 and z–57 ions to unambiguously call isoAsp at 0.18% with <8 ppm error—exactly the kind of fine-structure insight collision-only methods can miss. http://spr.ly/6043h8sB3 #OrbitrapExcedionPro #EASYETD #HCD #ETD #Proteomics #PTMs
5
1 Comment -
DC Maryland Virginia Biotech Networks
1K followers
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs https://lnkd.in/g6mMBNwG WILMINGTON, Del., March 12, 2026 /PRNewswire/ — Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), [...]
-
Biotech Networks
8K followers
bionetworks Trending News: Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors https://lnkd.in/gM9E3eqY SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #BreastCancer–Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in [...]
-
BIOCHINA
5K followers
🚨 China Biotech Update | First-Line CDK Inhibitor Filing 📅 On July 9, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. submitted NDA filings for two innovative therapies: 🔹 Kumosirli Capsules (a Class 1 CDK2/4/6 inhibitor) 🔹 Fulvestrant Injection (a Class 2.4 estrogen receptor degrader) 🔬 Based on public disclosures and clinical trial data, Insight estimates the indication to be: 💊 Kumosirli + Fulvestrant for previously untreated HR+/HER2- locally advanced or metastatic breast cancer. 📈 Another step forward for China’s innovative oncology pipeline on the global stage. #ChinaBiotech #BreastCancer #CDKinhibitor #OncologyInnovation #ChiaTaiTianqing #BIOCHINA2025 #DrugDevelopment
5
1 Comment -
Delagrave Life Sciences, LLC
26 followers
Noteworthy developments in biopharma and AI this week: 🧪 Nabla Bio × Takeda expand again: Multi-year collaboration around Nabla’s JAM (Joint Atomic Model) platform; “double-digit millions” upfront and >$1B in potential milestones. 🤖 AI for science: a major raise for Lila Sciences (Flagship's “AI Science Factory”), showing investor appetite for AI-driven wet-lab design loops that many protein-design shops rely on. https://lnkd.in/esrkQWNh https://lnkd.in/gFYhpg-v
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Guangcheng Jiang
34 others named Guangcheng Jiang are on LinkedIn
See others named Guangcheng Jiang